Cell Based Immunotherapy Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Cell Based Immunotherapy Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Cell-Based Immunotherapy Market is expected to register a CAGR of 15.5% during the forecast period, 2022-2027.

According to a study titled "Exploring metastatic breast cancer treatment changes during COVID-19 pandemic" published in the Journal of Chemotherapy in October 2020, it was observed that measures were taken to reduce access to hospitals for cancer patients in countries where the COVID-19 cases were massive such as Italy. Elective surgeries, follow-up appointments, and some types of cancer treatments were canceled or postponed prioritizing hospital beds and care for those patients who are seriously ill with COVID-19. Hence, COVID-19 adversely impacted the cell-based immunotherapy market.

In addition, the rising prevalence of cancer, technological advancement in developing target-based anti-cancer therapy, and launches and approval of different cell-based immunotherapy drugs are actively affecting the growth of the studied market.

For instance, Globocan Statistics 2020 reported that there are estimated 19.3 million cases of cancer among all age groups around the globe in 2020, and it is estimated to reach 30.2 million by 2040. The same source also reported that out of these cases, 1.15 million cases are of colon cancer, which is expected to reach 1.92 million by 2040. Such rapidly rising burden of different types of cancers are likely to boost the growth of the market over the forecast period.

Additionally, the advancements in products, increasing approvals, clinical trials along with partnerships and collaborations by key players are helping in the market growth. For instance, In June 2022 Immuneel Therapeutics, a biotech start-up commenced patient dosing in a CAR-T trial named IMAGINE. This phase II trial, which is currently actively enlisting patients in Bengaluru for clinical trial development, is one of the first industry-sponsored CAR-T trial in India. Such clinical trial developments are expected to augment the demand for cell based immunotherapy.

Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period. However, high cost of technology and lack of awareness in the developing markets is likely to impede the market growth.

Key Market TrendsChimeric Antigen Receptor (CAR) T-Cell Therapy Is Expected To Witness Significant Growth Over The Forecast Period

Chimeric antigen receptor (CAR) T-cell therapy is a significant advancement in cancer treatment. In this therapy patient's own T cells are genetically engineered to express an artificial receptor that binds to a tumor antigen. CAR-T cell therapy acts against CD19-coded cancer antigens to treat B cell cancers.

The rising prevalence of cancer, technological advancement in developing target-based anti-cancer therapies, and the increased adoption of cell-based therapy for therapeutic purposes are the key driving factors in the chimeric antigen receptor (CAR) T-cell therapy segment.

The International Agency for Research on Cancer (IARC) December 2020 update, indicated that the global new cancer burden has risen to 19.3 million cases and 10 million cancer deaths in 2020. It also stated that the estimated number of new cancer cases is projected to be 30.2 million by 2040. The increasing prevalence of cancer is likely to bolster the demand for chimeric antigen receptor (CAR) T-cell therapy for cancer treatment.

The advancements in therapy, approvals, launches, partnerships, and acquisitions by the key market players are likely to boost segment growth. For instance, in July 2020, Kite, a Gilead Company received the United States Food and Drug Administration approval for Tecartus, the first and only approved chimeric antigen receptor (CAR) T cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).

Also, in March 2021 the United States Food and Drug Administration approved Abecma (idecabtagene vicleucel), the first cell-based gene therapy to treat adult multiple myeloma patients who have not responded to at least four prior rounds of therapy. It is a genetically engineered chimeric antigen receptor (CAR) T-cell therapy directed by the B-cell maturation antigen (BCMA). Such approvals and advancements are likely to boost the segment's growth.

Therefore, there is a growth in the chimeric antigen receptor T-cell therapy segment of the studied market.

North America is Expected to Dominate the Cell Based Immunotherapy Market Over The Forecast Period

North America is expected to hold a significant market share in the global cell-based immunotherapy market due to the rising prevalence of cancer, the growing awareness of cell-based therapies, the strong presence of industry players, and better healthcare infrastructure in this region.

According to the American Cancer Society 2022 update, there are likely to be an estimated 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the United States in 2022. The same source stated that the estimated new breast cancer cases are 290,560, lymphoma cases are 89,010, pancreas cancer is 62,210, colon cancer is 106,180, and rectum cases are 44,850 in the United States in 2022.

Furthermore, ongoing research in cancer treatment, technological advancements, product approvals, launches, partnerships, and acquisitions by the key market players is also fueling the growth of the overall regional market to a large extent. For instance, in May 2022, a personalized cellular therapy developed by the Abramson Cancer Center at the University of Pennsylvania received United States Food and Drug Administration approval for the treatment of people with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.

Also, in May 2022 the chimeric antigen receptor (CAR) T-cell therapy Kymriah (tisagenlecleucel) of Novartis received the accelerated approval from the United States Food and Drug Administration making it the third indication for the country's first customized cellular therapy for cancer. It is still the only CAR-T cell therapy that has been authorized for use in both adult and pediatric patients. These initiatives are likely to augment the market growth.

Therefore, the studied market is anticipated to grow in the North American region due to the abovementioned factors.

Competitive Landscape

The Cell-Based Immunotherapy Market is consolidated and moderately competitive and consists of a few major players. The companies that are currently dominating the market are Novartis AG, Gilead Sciences, Inc (Kite Pharma), Apac Biotech, Dendreon Pharmaceuticals LLC, JW CreaGene Co., Ltd, and GC Biopharma Corporation

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.